Global health leaders discuss strategic medical innovation. From the left: Isabel Kumar (moderator), Monique Vledder (World Bank), Penny Heaton (Johnson & Johnson), Florika Fink-Hooijer (EU HERA), and Michael Lobritz (Roche).
Amid surging geopolitical tensions, increased global health threats, and strained public budgets, global health leaders and pharmaceutical executives converged in Geneva with a unified message: medical innovation must be treated as a critical investment not a healthcare drain. Showcasing this shift, Canada unveiled strategic investments and new regulations.
GENEVA – Inside the packed ballroom of the luxurious Intercontinental Hotel, during a flagship event hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Tuesday, large screens broadcast a simple promise of continuous innovation so that “the next generation…
